EUVIMEDEUVIMED entdecken
Crossref

Dermatophytosis: Clinical profile and resistance to itraconazole and terbinafine

Shivank Shrivastav

Bioinformation · 31.07.2026 · 22 (07) · 4528-4532

DOI: 10.6026/973206300224528 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Bioinformation, online erschienen am 31.07.2026. Verfasst von Shivank Shrivastav.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Globally, 20-25% of the population suffers from dermatophytosis. In India, there is an increase in treatment resistance and an epidemiological shift towards Trichophyton mentagrophytes. This was a prospective study, which randomized 500 patients of dermatophyte infection to either oral itraconazole or terbinafine to find out the rising treatment failure. Tinea cruris was the prevalent diagnosis (37.2%, M:F ratio 2.16:1), with Trichophyton mentagrophytes the commonest pathogen isolated. The clinical resistance of terbinafine was significantly higher than itraconazole (24.4% versus 5.2%, p < 0.0001). With no real mycological resistance found, clinical failure was mainly due to non-compliance (44.6%), diabetes and co-existing onychomycosis. Thus, data show the best first-line therapy is likely itraconazole and dealing with host co-morbidities probably overcomes treatment failure.

Zitieren

APA

Shrivastav, S. (2026). Dermatophytosis: Clinical profile and resistance to itraconazole and terbinafine. Bioinformation, 22(07), 4528-4532. https://doi.org/10.6026/973206300224528

Vancouver

Shrivastav S. Dermatophytosis: Clinical profile and resistance to itraconazole and terbinafine. Bioinformation. 2026;22(07):4528-4532. doi:10.6026/973206300224528

BibTeX
@article{Shrivastav2026,
  author = {Shrivastav, Shivank},
  title = {Dermatophytosis: Clinical profile and resistance to itraconazole and terbinafine},
  journal = {Bioinformation},
  year = {2026},
  volume = {22},
  number = {07},
  pages = {4528--4532},
  doi = {10.6026/973206300224528}
}
Kostenlos starten →